Business Wire

Planview Acquires AI/ML Leader Aptage

9.7.2020 17:03:00 EEST | Business Wire | Press release

Share

Planview® today announced the acquisition of Aptage, a technology leader and pioneer in the application of Artificial Intelligence (AI) and Machine Learning (ML) to portfolio management and work management.

Aptage’s expertise in data science is combined with unique domain knowledge in the economics of development spanning Agile and project methodologies. The company’s technology and IP is focused on the application of AI/ML to enterprise software, offering customers early insights and visibility into anticipated value and delivery risk across traditional project management and agile methodologies. For Planview customers, this ultimately means more accurate project outcome forecasting, regardless of work methodologies and processes used to get work done.

“In today’s disruptive environment, the companies with early insights are the ones that can pivot more quickly to create competitive advantage,” said Greg Gilmore, CEO of Planview. “Aptage’s innovative AI/ML technology creates insights into project value and delivery risk, improving and strengthening the strategy to delivery pipeline. We’re excited to welcome Aptage into the Planview family and bring this expertise to our customers.”

“Aptage and Planview share a common vision for the future of AI/ML within portfolio management and work management,” said John Heintz, co-founder and CEO of Aptage. “We’re thrilled to be taking this next step together, expanding the reach of our technology and driving better outcomes for organizations.”

Founded in 2016, Aptage’s proprietary IP was designed to accommodate the small data characteristics of Agile and traditional projects to continuously learn, predict, and provide actionable advice throughout the strategy to delivery pipeline. The technology has been proven with early adopters and is ready to scale to the mainstream market with Planview.

John Heintz, co-founder and CEO, and Dr. Murray Cantor, co-founder and CTO, will be joining Planview, bringing extensive experience and unique expertise to the company. Heintz is a recognized thought leader in the Agile and Lean community with 20 years of hands-on experience, and will be joining to lead product management for AI/ML. Dr. Cantor joins Planview as the company’s Chief Data Scientist, a new role created in recognition of the momentum in data science and the application of AI/ML in enterprise software.

Planview will be embedding the Aptage AI/ML IP across the Planview product portfolio. We anticipate the Aptage technology being available to customers later this year. To learn more, visit: Planview.com.

Additional Resources:

About Planview

Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions uniquely help organizations navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 700 employees supporting 3,500 customers and 1 million users worldwide. For more information, visit: https://www.planview.com/.

Planview and the Planview logo are registered trademarks of Planview, Inc. All other trademarks are property of their respective owners.

About Aptage

Aptage is a technology leader and pioneer in the application of Artificial Intelligence (AI) and Machine Learning (ML) to portfolio and work management, enabling companies to use their own data more intelligently through schedule, cost, and prioritization solutions. Companies using Agile, Waterfall, or hybrid frameworks have used Aptage to learn more from their project data and make informed business decisions based on AI advice. For more information, visit: https://get.aptage.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Planview
Leslie Marcotte, 719-439-4921
lmarcotte@planview.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corpay Cross-Border Extends Exclusive Partnership with WBSC6.10.2026 15:30:00 EEST | Press release

Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into a long-term agreement to extend their successful and exclusive collaboration as the Official Foreign Exchange (FX) Payments Provider of the World Baseball Softball Confederation (WBSC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261006279113/en/ Since 2022, Corpay Cross-Border has delivered a range of corporate foreign exchange payment solutions to the WBSC, the international governing body for Baseball/Softball. With this multi-year extension, the WBSC and their members around the globe will continue to benefit from Corpay’s comprehensive currency risk management solutions and award-winning global payments platform. “Over the past four years, we’ve had the privilege of serving as the Official FX Payments Provider for the WBSC,” said Brad Loder, Chief Marketing Officer, Corpay Cro

Agendia to Showcase New Research on AI-Driven Digital Pathology at ESMO 20266.10.2026 15:00:00 EEST | Press release

Agendia, Inc., a leader in precision oncology for breast cancer, announced today that it will present new research during a podium presentation on the development of an artificial intelligence (AI)-driven digital pathology approach for MammaPrintⓇ at the European Society for Medical Oncology (ESMO) Congress 2026, which takes place October 23 to 27, 2026, in Madrid. The company will also present two additional posters at ESMO. AI-driven digital pathology approaches are rapidly developing to expand access to genomic testing globally. Agendia’s first presentation, submitted as a late-breaking abstract, focuses on the development and validation of an AI-driven MammaPrint approach based on the analysis of routine whole slide images of breast cancer tissue. The following are details of the late-breaking abstract to be presented on the podium: PODIUM PRESENTATION: AI Driven Digital Pathology for the 70 Gene Recurrence Signature: Development and Validation in Early Stage Breast Cancer Presente

ExaGrid Named Finalist for the MSP Channel Insights Awards 20266.10.2026 15:00:00 EEST | Press release

ExaGrid, the world’s largest independent backup storage vendor providing Tiered Backup Storage for the fastest backups and restores, largest scale-out system with deduplication, and the most comprehensive security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that it has been nominated in seven categories for the annual MSP Channel Insights Awards. The MSP Channel Insights Awards celebrate innovation, expertise and success across the IT channel—recognizing the Managed Service Providers (MSPs), vendors, distributors, resellers and technology leaders driving customer outcomes and business growth. Voting to determine the winner in each category is underway now and closes on October 30, 2026. Winners of the MSP Channel Insights Awards will be announced on November 26, 2026, at an awards ceremony in London. The award categories that ExaGrid has been nominated for include: Vendor of the Year Vendor Channel Programme of the Year Data Protection & Backup Vendor of

IFF Identifies the Life-Stage Insights Shaping Dairy’s Future6.10.2026 14:00:00 EEST | Press release

IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, published its latest resource, Dear Dairy: The Life Stages Guide. This strategic guide reveals how manufacturers can unlock new opportunities by aligning dairy innovation with consumers' evolving needs throughout life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261005026164/en/ “Dairy is one of the few categories that evolves alongside consumers throughout their lives,” said Rogerio de Almeida Prado, vice president of Global Dairy & BBC (Bakery, Bars and Confectionery) for IFF Taste. “Over time, expectations change. What builds trust in childhood may need to support identity, convenience or vitality later in life. The next wave of dairy innovation will be defined not by a single trend, ingredient or claim, but by an understanding of what consumers need at different times of their lives — and why.” Drawing on insights from Panoptic™, IFF's

Invivoscribe ® Advances Molecular Clonality Testing Portfolio with Comprehensive LymphoTrack ® Flex Suite6.10.2026 13:15:00 EEST | Press release

Invivoscribe, a global leader in precision diagnostics and measurable residual disease (MRD) testing, today announced the launch of the complete LymphoTrack Flex suite, an integrated next-generation sequencing (NGS) solution to identify and track immunoglobulin and T-cell receptor gene rearrangements. As NGS-based immune receptor MRD analysis moves from academic laboratories into routine use in oncology research centers, the demand for standardized, high-throughput workflows is accelerating. Laboratories are seeking both greater efficiency and ultra-high sensitivity. This requires increasing DNA inputs while ensuring higher testing throughput and analytical performance. Translational programs need testing that is both reproducible and scalable across sites. LymphoTrack Flex meets these demands, bringing seven molecular targets (IGHV leader, IGH FR1, IGH FR2, IGH FR3, IGK, TRB and TRG), together in one automation-ready workflow with massively parallel multiplexing and a powerful bioinfo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye